| 前收市價 | 215.80 |
| 開市 | 215.60 |
| 買盤 | 211.90 x 0 |
| 賣出價 | 214.00 x 0 |
| 今日波幅 | 212.40 - 218.40 |
| 52 週波幅 | 177.95 - 266.00 |
| 成交量 | |
| 平均成交量 | 0 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年7月23日 - 2024年7月29日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
Investor's Business DailyEli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
Insider MonkeyBiogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during […]
ReutersEisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
